P

Inventor

GONG GUOCHUN

US19 patents
⚠️ This page may combine multiple inventors who share the name “GONG GUOCHUN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

18 patents
US8946505B2Feb 3, 2015

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA10 citations92
US8946504B2Feb 3, 2015

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA10 citations92
US9410163B2Aug 9, 2016

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA3 citations84
US11519004B2Dec 6, 2022

Transcription modulation in animals using CRISPR/Cas systems

REGENERON PHARMA4 citations71
US10285388B2May 14, 2019

Non-human animals having a disruption in a C9ORF72 locus

REGENERON PHARMA2 citations70
US12529072B2Jan 20, 2026

Transcription modulation in animals using CRISPR/CAS systems

REGENERON PHARMA0 citations61
US11730150B2Aug 22, 2023

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

REGENERON PHARMA0 citations61
US11547100B2Jan 10, 2023

Method for screening gene expression in lincRNA-deficient mice or rats

REGENERON PHARMA0 citations61
US11021719B2Jun 1, 2021

Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo

REGENERON PHARMA1 citations61
US10548302B2Feb 4, 2020

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

REGENERON PHARMA1 citations61
US11866794B2Jan 9, 2024

Cas-ready mouse embryonic stem cells and mice and uses thereof

REGENERON PHARMA0 citations59
US11547101B2Jan 10, 2023

Non-human animals having a disruption in a C9ORF72 locus

REGENERON PHARMA0 citations59
US11130999B2Sep 28, 2021

Cas-ready mouse embryonic stem cells and mice and uses thereof

REGENERON PHARMA1 citations59
US10196613B2Feb 5, 2019

Stem cells for modeling type 2 diabetes

REGENERON PHARMA0 citations52
US9677086B2Jun 13, 2017

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA0 citations52
US12521451B2Jan 13, 2026

CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy

REGENERON PHARMA0 citations51
US12582104B2Mar 24, 2026

Mutant myocilin disease model and uses thereof

REGENERON PHARMA0 citations50
US9554564B2Jan 31, 2017

IncRNA-knockout mice

REGENERON PHARMA0 citations50

FRENDEWEY DAVID

1 patent